Clinical trials: Multiple Sclerosis, Relapsing-Remitting
Multiple Sclerosis, Relapsing-Remitting
Delayed Diagnosis of Multiple Sclerosis, Treatment Initiation and Non-adherence in Upper Egypt
The earlier that MS can be diagnosed; the sooner treatment can be initiated with timely reduction of subclinical disease activity and prevention of disability progression.
- Trial name
- NCT05438693
- Where
- 2 sites in Egypt
- Volunteers
- 80 people
- Sponsor
- doaa mokhtar mahmoud
Relapsing-Remitting Multiple Sclerosis
Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta
This study is to find out if Interferon-beta (IFN-beta) can recover its effectiveness after a washout period in patients with Multiple Sclerosis who have previously developed neutralizing antibodies to Interferon-Beta
- Trial name
- RENeu (NCT00493116)
- Testing
- Interferon-beta-1a, methylprednisolone
- Where
- 2 sites in Australia, New Zealand
- Volunteers
- 20 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis (MS) Relapses
The efficacy of oral corticosteroids for the treatment of relapses of multiple sclerosis has not been proved. French neurologists treat such patients with intravenous corticosteroids.
- Trial name
- COPOUSEP (NCT00984984)
- Testing
- methylprednisolone PO, methylprednisolone IV
- Where
- 14 sites in France
- Volunteers
- 200 people
- Sponsor
- Rennes University Hospital
Multiple Sclerosis, Relapsing-Remitting
An Examination of Cognitive Fatigue Using Functional Neuroimaging
The purpose of this research study is to investigate the effectiveness of MS Disease modifying medications on cognitive fatigue in persons with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT04885894
- Testing
- Zeposia
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Kessler Foundation
Multiple Sclerosis
Depression and Fatigue in MS Patients Treated With Betaferon.
This study aims to evaluate the occurence and severity of fatigue and depression in multiple sclerosis patients and the impact of Betaferon treatment on symptoms alterations.
- Trial name
- FADO (NCT01354665)
- Testing
- Interferon beta-1b (Betaferon, BAY86-5046)
- Where
- Poland
- Volunteers
- 567 people
- Sponsor
- Bayer
Multiple Sclerosis (MS) - Relapsing-remitting
Effects of Ublituximab on Motor Functions in Multiple Sclerosis
The purpose of this study is to test if ublituximab changes walking functions and fall risk in people with relapsing multiple sclerosis (RMS). Twenty-five qualified people with RMS will undergo a 48-week ublituximab treatment.
- Trial name
- U-PACE (NCT06629428)
- Testing
- Ublituximab
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Georgia State University
Multiple Sclerosis, Relapsing Remitting
Differential Immune Effects of Natalizumab
Natalizumab is a humanized monoclonal antibody directed against Very Late Activation Antigene 4 (VLA-4) and has a potent effect on disease activity in multiple sclerosis (MS).
- Trial name
- NCT00859482
- Volunteers
- 27 people
- Sponsor
- Cantonal Hospital of St. Gallen
Multiple Sclerosis, Relapsing-Remitting
Light Therapy as Treatment for Fatigue in Multiple Sclerosis
This prospective study will randomize 1:1 people living with multiple sclerosis-associated fatigue to one of two spectra of light therapy.
- Trial name
- NCT03060759
- Testing
- Light Therapy box
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Massachusetts General Hospital
Multiple Sclerosis (MS) - Relapsing-remitting
Deuterium Metabolic Imaging in People with Multiple Sclerosis
The goal of this case-control study is to investigate glucose brain metabolism in people with multiple sclerosis and age- and sex-matched healthy controls.
- Trial name
- NCT06611280
- Testing
- No Interventions
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Multiple Sclerosis
Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b
Title: Efficacy, safety and tolerability of Atorvastatin 40 mg in patients with relapsing-remitting multiple sclerosis treated with interferon-beta-1b SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis Short…
- Trial name
- SWABIMS (NCT00942591)
- Testing
- Interferon beta 1b, Atorvastatin
- Where
- Switzerland
- Volunteers
- 77 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Multiple Sclerosis (MS) - Relapsing-remitting, Mediterranean Diet
Effect of Low Histamine-Based Modified Mediterranean Diet in Multiple Sclerosis
This randomized controlled trial will evaluate the effects of a low histamine-based modified Mediterranean diet in adults with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- HistaMed-MS (NCT07501520)
- Testing
- Low Histamine-Based Modified Mediterranean Diet, Traditional Mediterranean Diet
- Where
- Turkey (Türkiye)
- Volunteers
- 51 people
- Sponsor
- Firat University
Relapsing Remitting Multiple Sclerosis
Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya
A trial in patients with relapsing remitting multiple sclerosis (RRMS) Main objectives: To evaluate changes in the reconstitution of immune surveillance over time upon switching from natalizumab to fingolimod assessed by a change…
- Trial name
- ToFingo2 (NCT02325440)
- Testing
- Fingolimod, Natalizumab
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- University Hospital Muenster
Multiple Sclerosis
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
This is a randomized, double-blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and PK of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks (Q24W) in participants with RMS…
- Trial name
- MUSETTE (NCT04544436)
- Testing
- Ocrelizumab, Antihistamine, Methylprednisolone
- Where
- 120 sites in United States, Argentina and 19 more
- Volunteers
- 864 people
- Sponsor
- Hoffmann-La Roche
Relapsing-Remitting Multiple Sclerosis
Effects of Electromechanical Gait Trainer in Patients With Multiple Sclerosis
Multiple Sclerosis is a very disabling disorder in young adult patients leading to an important limitation in daily life activities and social participation.
- Trial name
- NCT01564511
- Testing
- Gait trainer treatment, Conventional treatment
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Universita di Verona
Relapsing-Remitting Multiple Sclerosis
An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis
Impaired short term memory, attention and concentration lapses, and slower processing of information occur in up to 40-65% of patients with Multiple Sclerosis (MS).
- Trial name
- NCT00398528
- Testing
- Glatiramer acetate, (Copaxone®), IFN-β-1a, (Avonex®)
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Neurognostics
Multiple Sclerosis, Relapsing-Remitting
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple sclerosis (RRMS) and to assess the pharmacokinetics (PK) of BIIB017 in pediatric…
- Trial name
- NCT03958877
- Testing
- BIIB017 (peginterferon beta-1a), Interferon beta type 1a
- Where
- 65 sites in United States, Argentina and 20 more
- Volunteers
- 152 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
Polymorphisms of Interleukins, Glypican, and Human Leukocyte Antigen Genes and Treatment Response in Multiple Sclerosis.
HLA-DRB1 * Gene and some genes involved in inflammation and immunity (IL-7R, GPC5, CTSS) have been linked to risk of MS and the response to treatment with immunomodulators.
- Trial name
- WESTEMDRB1 (NCT02769767)
- Testing
- Polymorphism of Interleukins, Glypican, and Human Leukocyte Antigen Genes.
- Where
- Mexico
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Instituto Jalisciense de Cancerologia
Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis
Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis
Idiopathic inflammatory disorders of the central nervous system include various disorders of which multiple sclerosis is the most common.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis, Controls, Multiple Sclerosis
- Trial name
- AMIS (NCT04201470)
- Testing
- Blood withdrawal, MRI, Neurologic / neuropsychologic tests - Patients
- Where
- France
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Relapsing Remitting MS, Secondary Progressive MS
Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis
Background/Rationale: Cognitive problems are a common symptom in individuals with Multiple Sclerosis (MS). Treatment options are limited, and there is a pressing need for new interventions to treat MS-related cognitive…
- Conditions
- Relapsing Remitting MS, Secondary Progressive MS, Primary Progressive MS
- Trial name
- NCT01848327
- Testing
- Caprylic Triglyceride
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- University of Miami
Relapsing Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis
"HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"
This protocol is part of a clinical study to evaluate efficacy and safety of multiple intravenous administrations of HB-adMSCs for the treatment of Multiple Sclerosis.
- Trial name
- MS (NCT06800404)
- Testing
- Autologous HB-adMSCs
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Hope Biosciences Research Foundation